e-therapeutics plc
ETXPF
$0.13
-$0.01-7.14%
OTC PK
| 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -8.20% | -5.49% | -43.94% | -49.87% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.20% | -5.49% | -43.94% | -49.87% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -8.20% | -5.49% | -43.94% | -49.87% | -- |
| SG&A Expenses | 22.07% | 25.81% | 8.12% | -3.30% | -35.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.45% | 28.25% | 51.99% | 35.94% | -13.16% |
| Operating Income | -25.49% | -29.32% | -58.20% | -41.49% | 15.82% |
| Income Before Tax | -28.39% | -32.31% | -51.64% | -35.63% | 22.15% |
| Income Tax Expenses | -16.31% | -19.85% | -51.21% | -35.25% | 8.73% |
| Earnings from Continuing Operations | -30.52% | -34.52% | -51.72% | -35.70% | 24.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.52% | -34.52% | -51.72% | -35.70% | 24.12% |
| EBIT | -25.49% | -29.32% | -58.20% | -41.49% | 15.82% |
| EBITDA | -25.57% | -29.51% | -60.58% | -43.63% | 16.31% |
| EPS Basic | -22.92% | -26.09% | -35.56% | -20.41% | 37.66% |
| Normalized Basic EPS | -22.86% | -23.53% | -35.29% | -22.22% | 36.36% |
| EPS Diluted | -22.92% | -26.09% | -35.56% | -20.41% | 37.66% |
| Normalized Diluted EPS | -22.86% | -23.53% | -35.29% | -22.22% | 36.36% |
| Average Basic Shares Outstanding | 5.79% | 5.79% | 11.95% | 11.95% | 21.54% |
| Average Diluted Shares Outstanding | 5.79% | 5.79% | 11.95% | 11.95% | 21.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |